Aspira Women's Health (AWH) Q4 2025 earnings summary

Executive summary

• Focused on AI-powered, noninvasive diagnostic tests for gynecologic diseases, with a strategic shift in 2025 to reduce cash burn and prioritize profitability through organizational streamlining and targeted commercial efforts.

• Maintained flat revenue year-over-year despite a 7% reduction in test volumes by focusing on higher-margin regions and profitable payer relationships.

• Expanded partnerships with major health systems, including Mayo Clinical Laboratories and Cleveland Clinic Foundation, to drive volume and access.

• Product pipeline includes ENDOinform for endometriosis and OVAinform for ovarian cancer, targeting large addressable markets.

Financial highlights

• Total revenue for 2025 was $9.2 million, nearly unchanged from 2024.

• Gross profit increased 8% to $5.9 million, with gross margin improvement due to higher average unit pricing.

• Operating loss reduced by 51% to $7.9 million, reflecting significant cost reductions in sales, marketing, and G&A.

• Net loss for 2025 was $12.8 million, a slight improvement from $13.1 million in 2024.

• Cash used in operations decreased by 40% to $7.0 million.

• Year-end cash and equivalents were $1.8 million, with a working capital of $0.6 million.

Outlook and guidance

• Management expects to incur a net loss and negative cash flows in 2026 and will require additional capital to continue operations.

• Plans to build on cost efficiency, improve average unit pricing, and increase unit sales in 2026.

• Ongoing focus on expanding payer coverage and reimbursement for OvaWatch and Oval.